| Names | |
|---|---|
| Preferred IUPAC name | (2R)-2-aminobutanedioic acid |
| Other names | D-Aspartate DAA D-Asp Aspartic acid (D-enantiomer) D-2-Aminobutanedioic acid |
| Pronunciation | /diː əˈspɑːrtɪk ˈæsɪd/ |
| Identifiers | |
| CAS Number | 1783-96-6 |
| Beilstein Reference | 63558 |
| ChEBI | CHEBI:16961 |
| ChEMBL | CHEMBL685 |
| ChemSpider | 12314 |
| DrugBank | DB00132 |
| ECHA InfoCard | 06de6b0e-8a40-49c6-b3c9-afd4f54ae8bb |
| EC Number | EC 200-733-6 |
| Gmelin Reference | **87448** |
| KEGG | C01080 |
| MeSH | D-Aspartic Acid"[MeSH] |
| PubChem CID | 4368 |
| RTECS number | TN8050000 |
| UNII | M79596U78A |
| UN number | UN9077 |
| Properties | |
| Chemical formula | C4H7NO4 |
| Molar mass | 133.10 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 0.98 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -3.89 |
| Vapor pressure | Negligible |
| Acidity (pKa) | 3.9, 10.0 |
| Basicity (pKb) | 2.02 |
| Refractive index (nD) | 1.632 |
| Viscosity | Powder |
| Dipole moment | 4.51 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 86.7 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -1176.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -1334.8 kJ/mol |
| Pharmacology | |
| ATC code | A16AA27 |
| Hazards | |
| Main hazards | May cause respiratory irritation. |
| GHS labelling | GHS07, Warning, H319 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Precautionary statements | Precautionary statements: If medical advice is needed, have product container or label at hand. Keep out of reach of children. Read label before use. |
| NFPA 704 (fire diamond) | 1-0-0 |
| Autoignition temperature | Autoignition temperature: 410°C (770°F) |
| Lethal dose or concentration | LD50 (rat, oral): > 5000 mg/kg |
| LD50 (median dose) | 9200 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | No PEL established |
| REL (Recommended) | 3,000 mg daily |
| IDLH (Immediate danger) | No IDLH established |
| Related compounds | |
| Related compounds | Aspartic acid N-Methyl-D-aspartic acid L-Aspartic acid Glutamic acid Homocysteic acid |
| Product Name | D-Aspartic Acid |
|---|---|
| IUPAC Name | (R)-2-Aminobutanedioic acid |
| Chemical Formula | C4H7NO4 |
| Synonyms & Trade Names | D-Asp; D-Aspartate; D-2-Aminosuccinic Acid |
| HS Code & Customs Classification | 2922.49 (Amino-acids and their esters, salts; category and code may vary depending on intended use and customs jurisdiction requirements) |
Each identification parameter for D-Aspartic Acid serves a regulatory, logistical, or technical intake purpose. The IUPAC name provides unambiguous international chemical identity, essential for registration and filing compliance. The molecular formula identifies the basic stoichiometry for traceability in both raw material audits and technical formulations.
Synonyms and commercial trade names are grade- and region-specific; for example, “D-Asp” references are common in feed and biochem sectors, but some import markets prefer standardized nomenclature to match local documentation. Proper synonym management minimizes confusion in customs clearance and GHS safety reporting.
HS code and customs classification require review tied to the product's declared function, with the tariff line subject to regular revision according to regulatory updates. Variants may fall under different headings if destined for pharmaceutical, food, or technical applications, and pre-shipment classification can involve direct engagement with local customs advisors.
Raw material selection influences optical purity and downstream impurity burden. D-Aspartic Acid produced via enzymatic resolution or stereoselective synthesis at scale must control both by-product generation and racemization risk. Sourcing decisions focus on chiral integrity, assessed through in-process chiral HPLC or equivalent methods, as even marginal D/L cross-contamination affects suitability for demanding life science projects.
Choice of production route (biocatalytic or synthetic) hinges on capacity, waste minimization, and capability to meet regional purity requirements. Pharmaceutical and food-grade material may require significantly different control points than technical grades, such as heavy metal screening or allergen risk management. In-process control includes strict monitoring of optical rotation, residual solvents, and mother liquor recycling conditions, which are key for consistent lot-to-lot reproducibility.
Release standards for each customer or market segment are based on grade-specific impurity thresholds, validated analytical methods, and batch records referencing agreed COA formats. Final specification alignment is the outcome of joint manufacturer-customer dialogue, often requiring tailored post-synthesis purification, reprocessing, or repackaging steps.
Product performance parameters such as particle size, bulk density, and flowability change in response to granulation techniques, milling, or agglomeration applied during downstream processing. Optimal selection of final form depends on targeted application—clinical nutrition, bioprocess feedstock, or industrial synthesis intermediate—each imposing different requirements for handling and dosing accuracy.
Shelf life and storage behavior vary with packaging materials and environmental exposure; typically, airtight and moisture-barrier systems reduce hydrolysis and aggregation risks, but storage protocols are made explicit only for each validated grade. Logistic decision-making incorporates destination climate, transit times, and local warehousing conditions to maintain product stability from plant to end user.
D-Aspartic acid typically presents as a white to off-white crystalline powder, though small differences in color tone may appear depending on purification grade and trace residuals from production. The compound has no significant odor. Melting point tends to vary slightly by batch, typically observed within 240°C to 250°C in unambiguous technical-grade samples. Industrial-grade material can contain residual moisture affecting apparent bulk density, which varies by granulation specification and downstream requirements.
The molecule remains structurally stable under conditions relevant for handling and storage, but exposure to strong oxidizers or bases can induce degradation or racemization. Assessment for compatibility with co-formulants in downstream applications forms part of release checks, especially for pharmaceutical and food-grade batches. pH stability in water solution is relevant for formulation scientists; solution stability depends on concentration and temperature, warranting testing under expected end-use conditions.
D-Aspartic acid dissolves in water with limited solubility, forming a clear to slightly opalescent solution when agitated. Solubility improves moderately by adjusting pH above the isoelectric point. For laboratory or industrial solution preparation, pre-dissolving the compound in warm water or adjusting pH with sodium or potassium salts is common. The operational solubility limit should always be checked against application-specific needs, as trace insolubles may originate from incomplete crystallization or micron-scale contaminants.
Specifications for D-Aspartic acid cover parameters such as chemical assay, moisture content, optical rotation, and trace impurity profiles. Exact values depend on application—pharmaceutical, nutraceutical, food, or industrial. Typical parameters set by regulatory guidelines or customer requirements are subject to periodic review. No single standard fits all: internal batch release relies on identifying the correct grade for the destination market and maintaining batch-to-batch consistency.
Impurity limits depend on synthesis pathway, downstream processing, and product end-use. Chiral purity receives particular scrutiny in biomedical applications. Residual inorganic salts, trace organic byproducts from synthesis, and heavy metals from upstream raw materials are common points of analysis. Detection thresholds and acceptance criteria reflect customer specification, with continuous trend analysis driving process adjustments.
Testing typically relies on high-performance liquid chromatography (HPLC) for content and purity, polarimetry for chiral identity, and validated wet methods for loss on drying and inorganic contaminant assessment. Standard reference methods may follow published pharmacopeial guidelines if targeting regulated industries, otherwise internal protocols guide acceptance based on historical process performance.
Raw material selection draws on purity, cost, and supplier reliability. Manufacturers may source precursor amino acids or relevant intermediates from regional suppliers who demonstrate consistent quality. Regulatory documentation for traceability forms part of incoming inspection, especially for medical and food-grade product. Process-specific impurities often trace back to raw material quality, so supplier audits remain standard practice.
Manufacturing routes include enzymatic resolution, microbial fermentation, or asymmetric synthesis, with route selection driven by scale, regulatory targets, and cost structure. Enzymatic or fermentation-based routes gain preference for chiral selectivity but require careful microbial strain or enzyme sourcing. Batch-to-batch optical purity depends on minimization of racemization and adequate removal of undesired isomers.
Key control points involve temperature, pH, and reactant feed rates during synthesis. Purification stages rely on crystallization, filtration, and washing to meet purity standards. Each step generates target and non-target fractions, monitored through in-process sampling and instrumental analysis. Multistage recrystallization is commonly applied for pharmaceutical and food-grade batches, while technical-grade product may employ abbreviated workups if customer requirements allow.
Quality teams release product based on internal batch records and analytical results. Release requirements account for specification drift, confirmed through trend analysis over production campaigns. Documentation includes traceability matrices linking raw materials, process parameters, and final product identity to satisfy customer and regulatory requests.
D-Aspartic acid participates in standard amino acid condensation and esterification reactions. Manufacturing chemists leverage the amino and carboxyl groups to access peptide derivatives or protected forms for intermediate use.
Typical reactions proceed in aqueous or polar organic solvents under mild to moderate temperatures. Acid or base catalysis may be used depending on the desired modification. Downstream processes employ deprotection or coupling steps, often under monitored pH and controlled temperature to prevent racemization or decomposition.
The compound serves as a precursor for specialty peptides, chemical intermediates, and in some routes, enantiopure materials for pharmaceutical syntheses. Modification potential targets site-specific labeling, conjugation, or protection depending on final product requirements.
Primary storage should occur in well-closed containers, protected from direct sunlight and high humidity. Recommended temperature conditions adapt to product grade: lower temperatures favor pharmaceutical and food-grade material, while ambient conditions often suffice for industrial batches. Oxygen- and moisture-barrier packaging extends shelf life and reduces hydrolytic or oxidative degradation risk.
High-density polyethylene containers provide effective long-term compatibility. Stainless steel vessels are suitable for bulk or in-process storage. Exposure to reactive metals or soft plastics may induce degradation or contamination.
Shelf life depends on purity, packaging, and storage conditions. Degradation appears as yellowing, agglomeration, or odor development, with loss in assay or increased levels of breakdown products confirmed during re-analysis. Product should be regularly checked against original specification before use in regulated applications.
Classification depends on regional regulatory inputs and batch impurity profile. Production-scale experience shows D-aspartic acid may not require hazard labeling at common concentration and exposure levels, yet confirmation with current safety data sheets is mandatory for all handling staff.
Standard practice recommends avoidance of dust inhalation and contact with eyes or skin. Production staff adopt personal protective equipment according to plant procedures. Risk assessments account for powder dispersal in handling and potential irritation of the respiratory tract.
Available literature does not report significant toxicity in standard laboratory or industrial use; pharmaceutical routes apply more stringent toxicological review. Evaluation of chronic exposure, reproductive endpoints, or system-specific impacts aligns with customer uses and submission dossiers.
No established occupational exposure limits apply to D-aspartic acid at typical production scales. Standard hygiene practices and effective local exhaust systems mitigate exposure. Spill management involves dry clean-up and avoidance of water runoff. Regular safety review and training contribute to maintaining low incident rates in manufacturing environments.
Industrial production of D-Aspartic Acid primarily relies on either chemical synthesis or enzymatic conversion pathways. Raw material availability, fermenter capacity, and downstream purification throughput set practical output limits. Production lines dedicated to amino acids are often scheduled around campaign production, requiring adjustments for campaign qualification, equipment cleaning, and raw material switching.
Output volumes depend heavily on grade requirements—pharmaceutical, food, and feed grades are scheduled separately due to distinct impurity profiles and release controls. Availability is subject to both internal quality control release and regulatory documentation timelines, particularly for pharmaceutical customers.
Standard lead times in this category are driven by production schedule, batch size, grade-specific requalification, and packaging format. Higher purity or tighter impurity specifications require additional analytical time. Typical minimum order quantities reflect batch campaign sizes and drum/pallet logistics; for D-Aspartic Acid, industrial users often require full-pallet increments, but smaller orders may be negotiable depending on backlog and campaign frequency.
Standard packaging for industrial transport favors fiber drums with inner liners for solid material and tamper-evident sealed bags for smaller batch or laboratory packs. Bulk customers may request PP super sacks or intermediate bulk containers, particularly when downstream dissolution or reprocessing occurs on customer premises. Packaging format selection is often driven by downstream cGMP requirements, traceability concerns, and supply chain climate sensitivity.
Shipment terms reflect both regulatory status (standard vs. regulated feedstock) and transport risk profile. Incoterms can vary, with FCA, FOB, and CIF most requested. Hazard assessment based on Physicochemical and REACH/TSCA status drives transport declarations. Standard payment schedules reflect grade, order size, and customer history, with rolling credit terms for established users and sight payment for new counterparties.
Feedstock for D-Aspartic Acid synthesis predominantly derives from aspartic acid or aspartate salts, with major input cost drivers being fermentation-grade glucose, ammonia, and proprietary enzyme or catalyst costs. Price sensitivity tracks global commodity cycles for corn, wheat, and chemical intermediates; price shocks in amino acid feedstocks or petrochemical derivatives ripple into production cost almost immediately for chemical synthesis processes.
Energy usage during synthesis and purification further affects delivered cost, with high purity and low endotoxin grades requiring extended multi-stage purification—raising both labor and utility cost per unit.
Prices for D-Aspartic Acid diverge sharply across grades. Pharmaceutical and high-purity food grades require tighter impurity controls, validated cleaning procedures, and extensive documentation—raising both batch failure risk and compliance cost. Feed and technical grades permit broader impurity ranges, translating to lower costs per kg. Certified packaging, such as ISO, BRCGS, or pharma-compliant containers, can add a significant cost per batch and slow lead time if validation or serialization is required.
Graded price differences reflect the cost not only of raw material and process, but batch record maintenance, stability studies, and customer-specific analytical testing, which escalate with higher value supply chains.
D-Aspartic Acid demand originates primarily from dietary supplement producers, diagnostic reagent manufacturers, and pharmaceutical synthesis. East Asia, particularly China, maintains the dominant share of manufacturing, thanks to integrated amino acid production clusters. North America and Europe purchase mainly for formulation, with local reprocessing or repackaging if GMP certification is required. Japan, India, and Southeast Asian economies act as both importers and secondary processors.
Supply disruptions most often stem from environmental regulation updates, feedstock shortages, and export policy changes in major producing countries. Lead time variability reflects local production cycles and international shipping capacity, especially across busy seasons and regulatory audits.
| Region | Market Feature | Supply Chain Comment |
|---|---|---|
| United States | Concentration in sports supplements, strict cGMP import controls | Preference shown for traceable, pharma- or food-grade imports; price premiums for documentation and rapid logistics |
| European Union | Regulated as both food additive and specialty ingredient | REACH compliance drives supply eligibility; testing and release standards result in long procurement timelines |
| Japan | Focus on high-purity reagent grade and diagnostic grade | Local re-testing, tight traceability protocols, reliance on supply outside China for critical applications |
| India | Expanding capacity for local dietary supplement market, slow adoption of highest grades | Price-sensitive buyers, variable regulatory scrutiny, mix of imported and indigenously produced material |
| China | Main producer and exporter; vertical integration with amino acid complexes | Bulk of global supply originates here; export policy and feedstock pricing remain key volatility drivers |
Looking forward, D-Aspartic Acid prices are expected to track raw material volatility—especially if agricultural input costs remain unstable and energy pricing globalizes further. Grade differentials may widen as more downstream users formalize documentation and certification demands. New environmental and traceability regulations—especially in the EU and US—create upward pricing pressure for controlled grades. If production consolidates further in East Asia following capacity expansions or environmental approvals, baseline pricing may fluctuate within a comparative band, but grade-specific premiums will intensify.
This outlook draws from trade flow data, customs statistics, internal production batch records, and third-party market research covering amino acid intermediates. Continuous input from long-standing customer order histories and ongoing dialogue with raw material suppliers further refines both availability estimates and pricing baselines.
Recent quarters have seen production interruptions tied to scheduled environmental audits and utility outages at several East Asian plants. Exporters in China have begun responding to increased documentation scrutiny from both North America and the EU, with tightening of out-bound batch release procedures.
Adjustment to REACH, TSCA, and new dietary supplement ingredient rules remain ongoing. Manufacturers supplying pharmaceutical and food grades have undertaken updated risk assessment and allergen declaration in response to evolving regulatory expectations. Ongoing efforts to validate eco-label and clean label statements reflect growing buyer sensitivity to both ingredient origin and process contaminants.
To manage volatility, producers maintain buffer inventory for high-grade stock and stagger production campaigns to match seasonal shipping congestion. Close attention to batch record transparency shortens recovery time after audit-related disruptions and supports rapid response to documentation inquiries. Long-term supply agreements with trusted logistics and raw input partners help mitigate price and supply shocks stemming from global energy, environmental, and regulatory swings.
D-Aspartic Acid enters production scenarios in nutraceuticals, pharmaceuticals, food ingredients, and specialty chemical synthesis. In-house, we focus on fit-for-use grade definition driven by critical points in each market. For nutritional supplements, customers expect ingredient identity and freedom from non-target amino acids. In pharmaceutical routes, limits on residual solvents, chiral purity, and microbial load govern suitability. Food customers request transparency in trace byproducts, while fine chemical buyers may prioritize processing aids or reactivity indices.
| Industry Field | Common Grade Types | Key Performance Features |
|---|---|---|
| Nutritional Supplements | Food Grade, Nutraceutical Grade | Chiral purity, heavy metals, residual solvent profile, batch homogeneity |
| Pharmaceutical Synthesis | Pharma Grade, Injectable Grade | Microbiological purity, low endotoxin, residual solvent threshold, full impurity profile |
| Food & Beverage | Food Grade, FCC-Conforming | Allergen status, batch-to-batch organoleptic consistency, traceability |
| Specialty & Fine Chemical | Technical Grade, Custom Specification | Specific impurity tolerances, particle size or flowability, reactivity in downstream process |
Nutraceutical and pharma buyers request detailed information on enantiomeric excess, microbial contaminants, and limits on formaldehyde traces. Food formulators prioritize all incoming raw data on cross-contamination, flavor neutrality, and solubility under process conditions. Specialty syntheses often demand custom impurity data and documented lot traceability for each campaign. The impact of these differences appears not only in final product safety but also in formulation process stability, shelf variance, and regulatory acceptance downstream.
Evaluate end-use needs before engaging for supply. For dietary products, define if the ingredient targets capsules, tablets, or functional blends. For therapeutic use, clarify administration route and finished dosage form. Each path shifts which technical benchmarks matter most during the supply discussion and sampling.
Request alignment with market-specific standards—this includes pharmacopoeial references, food safety codes, or REACH compliance as appropriate. Intended end-markets like Europe or North America may dictate different allowable impurity and contaminant profiles per local regulation or third-party audit requirement.
Set thresholds for chiral and chemical purity with the destination process in mind. Pharmaceutical clients frequently look for comprehensive impurity profiling beyond standard amino acid content. Nutritional and food buyers may need absence verification for non-D-alpha stereoisomers or fermentation byproducts depending on application sensitivity.
Assess required lot size, annual consumption, and desired supply continuity early. Higher purity or niche specifications often demand dedicated manufacturing campaigns, which impacts lead time and budgeting. Larger or frequent buyers may benefit from periodic quality review and synchronizing with our projected batch release cycles.
Before committing to full-scale delivery, request pilot lots or working samples for application testing. Most clients collect their own stability, formulation, and efficacy data to validate real-world performance. Manufacturers hold in-process retention samples and can expand purity or stability details if process troubleshooting arises at validation.
D-Aspartic acid manufacturing follows strict quality management system requirements. Our plants operate under certified management procedures. Auditors inspect batch traceability, documentation completeness, and record-keeping for all incoming raw materials, in-process checkpoints, and outgoing shipments. Plants achieving ISO 9001 credentials demonstrate ongoing process audits, deviation analysis, and corrective action review. Certificates align with customer sector needs; pharmaceutical or food-grade D-aspartic acid is only supplied under systems with documented GMP or FSSC 22000 frameworks, driven by regulatory and customer audits. Each certification outcome aligns with site-specific operational realities rather than applied as a blanket guarantee for every grade or batch.
D-Aspartic acid entering regulated markets requires grade-appropriate third-party verification. Application-driven requests—such as Halal, Kosher, or allergen-free statements—rely on both supplier documentation and in-plant process segregation. Production lines processing pharmaceutical or food-grade amino acids rely on controlled cleaning validation and allergen control documentation. Animal-origin-free declarations demand documented supplier transparency and batch-wise ingredient traceability. For industrial grades, certificate requirements set by downstream process users may vary according to integration with finished pharma or food final applications.
Each sale includes batch-specific certificates of analysis reflecting lot-specific analytical results. Analytical reports specify assay, moisture, and relevant heavy metal controls depending on grade and end-use segment. Release conforms to internally controlled analytical standards and, where requested, to client-specific test protocols. Audit support documents are made available through pre-arranged quality review or customer audit visits. Major deviations, if any, generate documented root cause analysis with systematic countermeasures. Final documentation and its granularity match compliance expectations for region or application, from feedstock through final product outturn.
Long-term D-aspartic acid planning with industry partners is based on in-depth raw material supply linkage and historical demand analysis. Manufacturing operations dedicate core capacity to contracted customers. Production scales flex to seasonal or campaign-based needs, especially when customer R&D cycles or regulatory approval times vary. Business arrangements may include scheduled forecast commitments, urgent resupply, and minimum order size flexibility, adjusted to support both steady and variable customer requirements.
Manufacturing teams control all major process steps, from raw acid source qualification to final crystal handling and packaging. Core capacity depends on plant-specific reactor throughput, purification train capability, and warehousing options. Batch scheduling and reserve inventory planning maintain supply continuity, especially for customers with high run-rate or regulatory-driven safety stock requirements. Sudden market shifts or supply interruption risks are managed by strategic buffer stock and multi-batch consignment planning, agreed in cooperation with the customer’s supply managers.
Sample requests involve direct coordination between our technical support and customer formulation teams. Samples are drawn from production-scale lots, not small pilot campaigns, to support representative downstream evaluation. Each dispatch includes batch history, test reports, and regulatory status if required by customer segment. Sample provision follows agreed documentation and chain-of-custody protocols, requested through direct manufacturer contact and assigned technical liaison for feedback collection and process refinement.
Procurement relationships depend on customer integration depth and market stability. Fixed-volume contracts suit high-volume integrated partners. Blanket orders work for customers with changing, but forecastable, requirements. Spot supply or batch trial cooperation uses process-by-process scheduling, often at customer project launch or regulatory trial phases. Multi-grade customers are supported by differentiated production plan allocation and unified logistics fulfillment, allowing customers to synchronize internal workflows with manufacturer batch processing. Handling special project needs, expedited orders, or regulatory-driven documentation is managed with direct technical and logistics support, rather than defaulting to standard shipment lead times or documentation cycles.
Recent laboratory and pilot-scale work has focused on process optimization for D-Aspartic Acid, especially in terms of fermentation route efficiency and impurity profile management. Screening for microorganisms with higher stereoselectivity and better substrate conversion rates dominates internal R&D efforts, as raw material costs and purification steps impact production economics directly. Research teams also prioritize impurity reduction strategies, targeting trace amino acid isomers and reducing byproduct load during crystallization steps.
Process engineers track trends in solvent-free production and membrane-based purification. Process safety and energy intensity remain critical evaluation points at scale-up. QA teams actively monitor racemization rates during long-term storage and are working to establish robust stability indicators for various grades.
Application laboratories have reported increased requests from specialized nutritional and pharmaceutical customers. Key application trends involve demand for D-Aspartic Acid in sports nutrition formulations and reproductive health sector, where specific bioactivity profiles drive raw material selection. Formulation chemists in peptide synthesis and chiral intermediate segments signal higher volume requirements, with tighter controls on metal content and byproduct amines.
Customers in the feed additive sector evaluate D-Aspartic Acid for animal performance optimization, seeking consistent lot-to-lot release and traceability on precursor amino acids.
Persistent technical challenges include minimizing racemization during both production and storage, and ensuring high enantiomeric purity without excessive yield losses. Scale-up engineers identify filtration and drying as critical bottlenecks—membrane fouling and crystal agglomeration complicate continuous processes. Where customer applications demand sub-ppm levels of certain metal ions or organic residuals, purification cost becomes the primary limiting factor.
Analytical teams are expanding the use of chiral HPLC methods, and recent improvements in rapid screening facilitate higher throughput for quality assessments. One notable breakthrough lies in recycling mother liquors through targeted pH adjustments, increasing overall process yield without elevating impurity carryover.
Based on current demand signals from functional food and life science sectors, internal forecasts predict a steady rise in industrial D-Aspartic Acid consumption through 2028. Market expansion is tied closely to downstream ingredient registration trends and regulatory sync with major consumer regions. Growth potential remains sensitive to changes in import tariffs, raw material pricing, and introduction of competing chiral products.
Further, custom applications in pharmaceutical intermediates are expected to outpace commodity-grade usage, with differentiated supply chains and quality standards defining price competitiveness.
Process technology continues shifting toward lower-waste syntheses and reduced solvent input. Recent investment in enzymatic racemization inhibitors has started to bear fruit, with measurable impacts on long-term product stability. Uptake of in-line analytics and PAT (Process Analytical Technology) tools supports faster process development cycles and tighter quality releases.
Downstream, shifts toward continuous crystallization and integrated impurity removal reflect both regulatory requirements and customer-specific needs for higher batch-to-batch consistency.
Environmental benchmarking compares each process route’s energy intensity, water input, and non-recyclable byproduct output. Green chemistry principles drive internal adoption of advanced waste minimization approaches, including selective ion-exchange and solvent recovery.
Material sourcing teams emphasize traceable, low-impact feedstocks, where the supply chain can guarantee origin and minimize environmental burden. Product stewardship programs have built-in customer feedback loops addressing process safety, lifecycle impacts, and extended producer responsibility. These focus areas underpin ongoing technical development as regulatory and customer priorities evolve.
Customers engaging in new applications often request full impurity profile data and support on product suitability per sector-specific guidance. Our in-house chemists provide technical consultation to help customers interpret analytical results compared against their own in-process requirements. Process specialists advise on raw material compatibility, solubility, and downstream blending for both batch and continuous operations.
Application engineers assist formulation teams with troubleshooting integration issues, such as solubility in high-load systems and stability under varying pH or temperature programs. The support scope includes optimization recommendations based on actual production trial feedback and direct sample-lot testing under customer-specific protocols.
Where customers require lot-specific statements regarding allergens, metal content, or enantiomeric excess, we align technical outputs against regulatory registration files and internal batch records, ensuring responsive documentation turnaround.
The after-sales service framework covers product quality assurance, change notification protocols, and non-conformance management. Batch records, retain samples, and release specifications remain accessible for verification through the product’s use period, with extension possible per customer agreement. Dedicated support teams facilitate root cause investigations and continuous improvement feedback, maintaining transparency on capability upgrades and future process enhancements.
Customers can access ongoing support through structured complaint resolution, sample resupply, and tailored guidance for any future application adjustment, reflecting the technical partnership approach of our manufacturing organization.
Manufacturing D-Aspartic Acid in-house provides full oversight from raw material selection through to final dispatch. Every step in the process draws on strict in-plant controls and decades of specialized experience with amino acid synthesis. This keeps purity, particle profile, and assay within tight limits batch after batch, supporting demanding technical and regulatory specifications.
D-Aspartic Acid serves as a key reagent and intermediate in several fields. In nutritional and feed production, it supports enrichment formulas and specialty protein mixes. Within technical applications, it acts as a building block for bio-based polymers, active pharmaceutical ingredients, and enantioselective catalysts. Manufacturers operating in contract synthesis, life sciences, and materials R&D depend on this input for reproducible downstream outputs.
Maintaining stable quality defines our approach. Every production run passes through analytical and performance benchmarks using validated methods. Routine microbial and heavy metal screening, LC-MS, and HPLC profiling verify composition and meet market requirements for food, feed, and pharma inputs. This attention to detail reflects direct plant accountability, not outsourced promises.
D-Aspartic Acid leaves our facility in a range of bulk and small pack formats, engineered for shipping stability and floor handling. Multi-layer anti-contamination liners, durable drums, and custom weight fills are available to align with your plant materials intake needs. Our logistics team controls outbound flows and schedules according to confirmed demand, giving buyers a transparent view from production planning to ex-plant dispatch.
Application chemists, process engineers, and procurement specialists often seek precise information for line trials, process optimization, and compliance assurance. Our technical support group responds with factual documents, batch traceability, and hands-on assistance for questions around blending, reactivity, or downstream impact. This practical, first-hand guidance helps manufacturers solve real floor-level challenges, especially when adapting D-Aspartic Acid for novel formulations or scale-up projects.
| Segment | Operational Benefit |
|---|---|
| Manufacturing Plants | Consistent feedstock reduces run-time variability and rework costs. |
| Distributors | Reliable availability and predictable specification aid in inventory and demand planning. |
| Procurement Teams | Direct manufacturer interface streamlines tendering, ensures batch transparency, and minimizes sourcing risk. |
| R&D/Process Development | Technical dialogue supports compliance, formulation, and process troubleshooting at laboratory and plant scale. |
A D-Aspartic Acid program supported by on-site manufacturing brings measurable gains to supply chain integrity, cost control, and production resilience. Every batch carries the marks of direct plant discipline and ongoing investment in product performance for commercial and technical partners worldwide.
At our facility, the production of D-Aspartic Acid follows a strict protocol from raw materials through to finished goods. All synthesis steps take place in our own workshops, and purification runs are conducted under controlled conditions managed by our trained production chemists. We monitor every batch closely, setting targets and performing critical in-process checks. Our goal each time is to supply D-Aspartic Acid at or above 99.0% purity, as measured on a dry basis. This high standard matches the requirements of consistent, high-performance applications in the biochemical and nutraceutical sectors.
Each lot is run through a detailed verification process. Our quality control laboratory uses high-performance liquid chromatography (HPLC) as the principal analytical method for determining material purity. The technique provides clear resolution between D- and L-isomers, so we catch even low-level impurities or residual starting materials that other tests might miss. We calibrate our instruments daily with certified standards, logging the calibration and all batch results as part of our internal record-keeping.
Our technical staff supplements HPLC with additional analytical tools where appropriate. We use specific optical rotation tests to confirm the correct enantiomer, as D- and L-Aspartic Acid show measurable differences. For further assurance, we may use infrared spectroscopy (IR) to verify functional groups and check for the presence of contaminant amino acids. Another step in our verification protocol involves loss on drying and ash content determinations, both of which provide secondary checks for non-amino acid impurities.
Our operations keep physical isolation between the D- and L- manufacturing lines. This greatly reduces the risk of cross-contamination, a concern that can become costly for active ingredient users. All packaging is clearly labeled, and we store dedicated records for each production run, tying verification data directly to each shipment.
With more brands and researchers using D-Aspartic Acid across food tech, pharma, and sports nutrition industries, high batch-to-batch consistency is critical. Analytical accuracy means a lot — a variation of even half a percent can matter for both downstream formulations and regulatory reporting. By maintaining up-to-date analytical protocols and reviewing batch data, we keep our customers confident about the quality entering their operations.
We routinely review our verification standards to match current best practices. If a customer requests a new testing protocol or documentation standard, our R&D specialists are prepared to engage and update our process. All product documentation accompanies shipments, including certificates of analysis with full disclosure of test methods and instrumentation.
This approach is how we build long-term relationships with partners who expect reliable quality at scale, year after year. In a market where traceability and compliance are under close watch, we see transparency and technical rigor in purity testing as the basic foundation for business.
Placing a bulk chemical order isn’t just about capacity; it’s about fitting product movement, storage, and safety within an operation. As the direct manufacturer, we provide several bulk packaging options for our full product line, based on decades of hands-on production, handling, and logistics experience. We manage packaging in-house and constantly re-evaluate solutions as customer needs and industry standards evolve. For most orders, our standard options include 25 kg woven bags, 500 kg to 1,000 kg flexible intermediate bulk containers (FIBCs, often called “big bags”), and steel or HDPE drums ranging from 50L to 200L. For large-scale liquid products, we also offer 1,000L intermediate bulk containers (IBCs) and bulk tanker truck deliveries when suitable.
Standardization matters to us because repeatability and safety both start with packaging. Testing each packaging solution in our production facility means every palletized bag or filled drum meets regulatory and practical requirements for the substance inside. We source raw packaging materials directly and verify the integrity before each production run. Consistent inward monitoring has helped us reduce waste and claims at our customer sites. We’ve responded to customer requests for innovation too. For powder products, low-dust and anti-static liners are common requests in both 25 kg bags and FIBCs. Hazardous materials demand UN-rated drums and rigorous inspection. Every packaging type we offer has a dedicated process line in our plant to avoid cross-contamination.
Lead time on bulk orders isn’t just about putting product in a bag—it covers raw material procurement, production slotting, packaging prep, quality control sampling, and logistics arrangement. We maintain strategic raw material stocks to serve repeat orders with minimal delay. Standard products in routine packaging usually ship within five to twelve business days of order confirmation. For custom packaging, complex formulations, or unusually large lots, the production team builds out a tailored schedule and confirms the timeline at the start. Over the years, we’ve integrated multisite capacity planning software and expanded warehouse storage. This has allowed us to handle both just-in-time delivery for multi-site customers and emergency requests for critical supply chains during market disruptions.
Our operations staff coordinate each step, from packaging supply to finished product readiness. This means keeping in close contact with our logistics partners, reviewing local regulatory changes, and lining up the right certificate documents before product leaves our site. On rare occasions, freight capacity or customs bottlenecks may influence proposed lead time—our front office provides updates quickly and transparently if a delay is likely.
We regularly document and analyze our shipment turnaround, package integrity claims, and customer feedback. Last year’s data showed 98.7% of bulk orders shipped on time, and only a handful required any package correction on arrival. Our technical team works with production planners to balance up-to-date demand forecasting, batch production, and packaging stock. Customers asked us to review packaging sustainability, so today nearly all our packaging materials are recyclable or reusable, with full material traceability available by batch number. Product-specific handling guidelines, shelf life, and packaging compatibility can be provided in detail through our technical documents on request.
Every batch and package we ship is backed by direct manufacturer control and operational know-how, so ordering bulk chemical products from us means gaining end-to-end accountability. For bulk chemical buyers, real value lies in a manufacturer’s ability to keep packaging practical, timetables honest, and support ongoing—even as industry standards move forward.
Our D-Aspartic Acid comes straight from our production floor, and we base every batch on regulatory requirements that set the standard across industries. Global customers work under strict regulatory oversight, so we bring their compliance needs to the center of our quality management program.
REACH regulation shapes the manufacturing and distribution of chemical substances in the European Union. We invest significant resources in registering our D-Aspartic Acid according to its requirements and staying current as the framework evolves. Our compliance covers full documentation, hazard communication, and high-purity content. For industries that rely on USP (United States Pharmacopeia) benchmarks, our process targets those guidelines right from raw material selection through final testing.
Routine operations at our facility don’t treat GMP (Good Manufacturing Practice) as a checklist. Our technicians and plant managers follow strict SOPs and batch record reviews. Each production run gets unique identifiers, and all work instructions shape sanitation, raw ingredient verification, in-process monitoring, product filtration, and packaging. Regular internal audits challenge our process to avoid drifting away from set practice.
Products for nutrition, pharmaceutical, and laboratory use move through secure handling and storage steps to prevent cross-contamination or quality drift. Instrument calibration schedules remain up-to-date, and staff go through recurrent training. Adherence to GMP enables us to pass regular customer and regulatory inspections, but more than that, it mitigates operational risks and delivers the consistent batch-to-batch quality that our buyers rely on.
A batch’s journey finishes with analytical verification and documentation, not just a shipping label. Our in-house quality control team issues a Certificate of Analysis based on physical and chemical parameters for every lot. This document captures key results such as purity assay, moisture, endotoxin, and heavy metals—measured on validated instruments. Our COA format gives downstream users the traceable, signed-off data they need for regulatory records and internal audits.
Alongside the COA, we attach a Safety Data Sheet (SDS) formatted for international standards. Our SDS spells out hazards, handling, transport, storage, and first-aid measures, referencing up-to-date regulatory registers. Both the COA and SDS travel with each shipment—whether consignments move by airfreight, ocean, or ground.
It is easy to view regulatory compliance as a paperwork burden, but we see it as part of the product itself. Many sectors prefer to partner with a manufacturer that documents quality with precision. Having aligned our D-Aspartic Acid production with REACH, USP, and GMP principles, customers avoid the delays or legal hurdles that arise when certification or data are missing. Our technical support team stands ready to answer complex regulatory questions, address audits, and ensure paperwork is in place before product release.
For us, compliance does not just tick boxes. It demonstrates respect for the scientific process, customer safety, and sustained partnership value. We keep our technical files updated and support every shipment with a COA and SDS, helping manufacturers, formulators, and researchers deliver their own promises to regulators and end users.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
